Abstract
Ischemia and heart failure-related cardiac arrhythmias, both atrial (e.g., atrial fibrillation) and ventricular (e.g., malignant tachyarrhythmias) represent a leading cause of morbidity and mortality worldwide. Despite the progress made in the last decade in understanding their pathophysiological mechanisms there is still an unmet need for safer and more efficacious pharmacological treatment, especially when considering the drawbacks and complications of implantable devices. Cardiac ATP-sensitive potassium channels located in the sarcolemmal membrane (sarcKATP) and the inner mitochondrial membrane (mitoKATP) have emerged as crucial controllers of several key cellular functions. In the past three decades a tremendous amount of research led to their structural and functional characterization unveiling both a protective role in cardiac adaptive responses to metabolic stress and a seemingly paradoxical role in promoting as well as protecting against atrial and ventricular arrhythmias. On the other hand, several KATP inhibitors have emerged as potential ischemia selective antiarrhythmic drugs. In this respect, cardioselective, chamber specific and combined sarcKATP and mitoKATP modulators currently represent a promising field for drug development.
Keywords: Sarcolemmal and mitochondrial ATP-sensitive potassium channels, cardiac arrhythmias, pharmacological modulators.
Current Pharmaceutical Design
Title:ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Volume: 21 Issue: 8
Author(s): Danina M. Muntean, Lorand Kiss, Norbert Jost and Istvan Baczko
Affiliation:
Keywords: Sarcolemmal and mitochondrial ATP-sensitive potassium channels, cardiac arrhythmias, pharmacological modulators.
Abstract: Ischemia and heart failure-related cardiac arrhythmias, both atrial (e.g., atrial fibrillation) and ventricular (e.g., malignant tachyarrhythmias) represent a leading cause of morbidity and mortality worldwide. Despite the progress made in the last decade in understanding their pathophysiological mechanisms there is still an unmet need for safer and more efficacious pharmacological treatment, especially when considering the drawbacks and complications of implantable devices. Cardiac ATP-sensitive potassium channels located in the sarcolemmal membrane (sarcKATP) and the inner mitochondrial membrane (mitoKATP) have emerged as crucial controllers of several key cellular functions. In the past three decades a tremendous amount of research led to their structural and functional characterization unveiling both a protective role in cardiac adaptive responses to metabolic stress and a seemingly paradoxical role in promoting as well as protecting against atrial and ventricular arrhythmias. On the other hand, several KATP inhibitors have emerged as potential ischemia selective antiarrhythmic drugs. In this respect, cardioselective, chamber specific and combined sarcKATP and mitoKATP modulators currently represent a promising field for drug development.
Export Options
About this article
Cite this article as:
Muntean Danina M., Kiss Lorand, Jost Norbert and Baczko Istvan, ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update, Current Pharmaceutical Design 2015; 21 (8) . https://dx.doi.org/10.2174/1381612820666141029102800
DOI https://dx.doi.org/10.2174/1381612820666141029102800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Current Drug Targets Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Regulation of HIPK Proteins by MicroRNAs
MicroRNA Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Cardiac Role of the Transcription Factor NF-κB
Cardiovascular & Hematological Disorders-Drug Targets c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL
Current Drug Targets Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Expression and Function of MicroRNAs in Enamel Development
Current Stem Cell Research & Therapy TNFα as Therapeutic Target: New Drugs, More Applications
Current Drug Targets - Inflammation & Allergy Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Cardiovascular Magnetic Resonance Imaging: State of the Art
Current Cardiology Reviews Biological and Pharmacological Activities of Iridoids: Recent Developments
Mini-Reviews in Medicinal Chemistry Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry